⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Wayshine Biopharm and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Wayshine Biopharm
↗Shanghai, China
Wayshine Biopharm is a clinical-stage biopharmaceutical company focused on the research and development of innovative anti-cancer drugs. The company specializes in developing precision medicines, particularly small-molecule inhibitors designed to penetrate the blood-brain barrier (BBB) for the treatment of various cancers, including glioblastoma (GBM) and non-small cell lung cancer (NSCLC).
Founded in 2016, the company utilizes functional genomics to identify biological targets and collaborates with local and international Contract Research Organizations (CROs) for drug screening and development. Their pipeline is heavily focused on addressing unmet medical needs in oncology, with several candidates receiving Orphan Drug Designation and Breakthrough Therapy Designation.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2016
Ownership:private
Status:operating
FUNDING
Stage:Pre-IPO
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Small molecule
Active Trials:4
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Wayshine Biopharm (Hangzhou) Co. Ltd
Key Partnerships:Mayo Clinic (Clinical research collaboration), Yale Medical School (Research support)
COMPETITION
Position:Emerging
Competitors:Hutchison MediPharma, Taiho Oncology, Hoffman Roche
LEADERSHIP
Key Executives:
Wei Zhong - CEO/Founder
Zhihua Mu - Cofounder
Claire Sun - Cofounder
Scientific Founders:Wei Zhong
LINKS
Website:wayshinebiopharm.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Wayshine Biopharm. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.